Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771163 | 0.98 | TSHR (0.55) | TSHRHPGDGAAALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL2057759 | 0.94 | TSHR (0.55) | TSHRHPGDGAAALDH1A1MAPT | |
| Acetic Acid SCHEMBL30499237 | 0.93 | TSHR (0.50) | TSHRHPGDGAAALDH1A1MAPT | |
| SCHEMBL10202112 | 0.92 | TSHR (0.57) | TSHRHPGDGAAALDH1A1MAPT | |
| SCHEMBL1778423 | 0.92 | TSHR (0.57) | TSHRHPGDGAAALDH1A1MAPT | |
| SCHEMBL2681321 | 0.92 | TSHR (0.57) | TSHRHPGDGAAALDH1A1MAPT | |
| SCHEMBL1631699 | 0.84 | — | — | |
| SCHEMBL26953125 | 0.84 | — | — | |
| SCHEMBL20601119 | 0.79 | HPGD (0.50) | TSHRHPGDGAAALDH1A1KMT2A | |
| SCHEMBL19917124 | 0.79 | KMT2A (0.50) | TSHRHPGDGAAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866435-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4292650-A2 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| US-11807618-B2 | Thiophene derivatives as antiviral agents | ENYO PHARMA (FR) | 2023-11-07 | — | — | US | disclosed |
| US-20230100875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-03-30 | — | — | US | disclosed |
| US-11535615-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220213053-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | ENYO PHARMA (FR) | 2022-07-07 | — | — | US | disclosed |
| EP-3562818-B1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | ENYO PHARMA (FR) | 2022-05-18 | — | — | EP | disclosed |
| US-11279683-B2 | Thiophene derivatives as antiviral agents | ENYO PHARMA (FR) | 2022-03-22 | — | — | US | disclosed |
| EP-3828171-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20200407357-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-12-31 | — | — | US | disclosed |
| WO-2000009104-A2 | USE OF SULFONAMIDES FOR TREATING VISION AND MEMORY DISORDERS | GPI NHL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999062490-A1 | SMALL MOLECULE SULFONAMIDE HAIR GROWTH COMPOSITIONS AND USES | GPI NIL HOLDINGS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| US-5968957-A | ADMINISTERING TO EFFECT NEURONAL ACTIVITY | GPI NIL HOLDINGS, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0923547-A1 | BIDENTATE METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998035675-A1 | METHOD OF USING NEUROTROPHIC SULFONAMIDE COMPOUNDS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998008814-A1 | BIDENTATE METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| US-5721256-A | INHIBITORS OF THE ENZYME ACTIVITY ASSOCIATED WITH IMMUNOPHILIN PROTEINS | GPI NIL HOLDINGS, INC. (US) | 1998-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407357-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | GAA 2040/4885TSHR 2281/4885HPGD 73/4885 |
| US-20220213053-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | MAVS, EIF2AK2, IRF3 | GAA 355/4885TSHR 2788/4885HPGD 4196/4885 |
| US-20230100875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | GAA 2040/4885TSHR 2281/4885HPGD 73/4885 |
| US-11535615-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | GAA 2040/4885TSHR 2281/4885HPGD 73/4885 |
| US-11866435-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | GAA 2040/4885TSHR 2281/4885HPGD 73/4885 |
| US-11279683-B2 | Thiophene derivatives as antiviral agents | MAVS, EIF2AK2, IRF3 | GAA 238/4885TSHR 2325/4885HPGD 4008/4885 |
| US-11807618-B2 | Thiophene derivatives as antiviral agents | MAVS, EIF2AK2, IRF3 | GAA 355/4885TSHR 2788/4885HPGD 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.